Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,331,440
  • Shares Outstanding, K 109,276
  • Annual Sales, $ 6,711 M
  • Annual Income, $ 2,444 M
  • 36-Month Beta 1.27
  • Price/Sales 6.76
  • Price/Cash Flow 18.68
  • Price/Book 5.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 5.24
  • Number of Estimates 1
  • High Estimate 5.24
  • Low Estimate 5.24
  • Prior Year 3.98
  • Growth Rate Est. (year over year) +31.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
393.17 +7.83%
on 01/23/19
431.32 -1.70%
on 02/01/19
+18.95 (+4.68%)
since 01/15/19
3-Month
331.54 +27.88%
on 11/20/18
431.32 -1.70%
on 02/01/19
+82.32 (+24.09%)
since 11/15/18
52-Week
281.89 +50.40%
on 05/09/18
431.32 -1.70%
on 02/01/19
+90.79 (+27.25%)
since 02/15/18

Most Recent Stories

More News
U.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor

Today the European Patent Office invalidated Immunex's European patent claiming antibodies that target human IL-4 receptors (IL-4R)

REGN : 423.97 (+2.17%)
AMGN : 188.34 (+0.89%)
Look for Shares of Regeneron Pharm to Potentially Pullback after Yesterday's 1.85% Rise

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $416.62 to a high of $422.66. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high...

REGN : 423.97 (+2.17%)
Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the Cowen 39th Annual Healthcare Conference at 11:20 a.m. ET on Monday, March 11, 2019.

REGN : 423.97 (+2.17%)
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

MGNX : 21.84 (+3.41%)
LGND : 120.86 (-0.02%)
INCY : 84.15 (+0.88%)
GILD : 67.59 (+1.84%)
SGEN : 71.48 (+4.24%)
REGN : 423.97 (+2.17%)
Ophthalmic Drugs Market 2018 Global Industry Analysis, Size, Application Analysis, Regional Outlook, Competitive Strategies And Forecasts, 2023

An expert on premium research reports, Market Research Future has added a report titled to its offering. The report provides an in-depth analysis of regional data and an accurate projection of the market...

VRX.TO : 30.80 (-3.33%)
SNPHF : 14.8000 (-2.31%)
MRK : 79.81 (+1.10%)
AGN : 139.07 (+0.29%)
SHPG : 179.20 (+4.10%)
TEVA : 17.98 (+4.05%)
REGN : 423.97 (+2.17%)
PFE : 42.40 (+1.02%)
Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?

Is (REGN) Outperforming Other Medical Stocks This Year?

REGN : 423.97 (+2.17%)
Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%

Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.

CI : 197.87 (+2.94%)
REGN : 423.97 (+2.17%)
AMGN : 188.34 (+0.89%)
SNY : 42.55 (+2.38%)
New Research Coverage Highlights Overstock, Regeneron Pharmaceuticals, Molecular Templates, The Ensign Group, Limoneira, and Primo Water -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Overstock.com, Inc. (NASDAQ:OSTK),...

LMNR : 23.36 (+1.70%)
PRMW : 14.03 (+2.11%)
MTEM : 4.66 (+3.56%)
REGN : 423.97 (+2.17%)
ENSG : 52.19 (+3.51%)
OSTK : 19.73 (+2.92%)
Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price

Praluent® (alirocumab) will be made available at a new reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March....

SAN : 4.64 (+2.65%)
REGN : 423.97 (+2.17%)
SNY : 42.55 (+2.38%)
Ophthalmic Drugs Market to Expand at a steady Growth Rate in the Coming Years

The global ophthalmic drugs market is expected to register significant growth in the forecoming years. Major factors driving growth of the global ophthalmic drugs markets are, increasing prevalence and...

VRX.TO : 30.80 (-3.33%)
SNPHF : 14.8000 (-2.31%)
AGN : 139.07 (+0.29%)
NVS : 89.88 (+0.97%)
SHPG : 179.20 (+4.10%)
TEVA : 17.98 (+4.05%)
REGN : 423.97 (+2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 430.03
1st Resistance Point 427.00
Last Price 423.97
1st Support Level 418.33
2nd Support Level 412.69

See More

52-Week High 431.32
Last Price 423.97
Fibonacci 61.8% 374.24
Fibonacci 50% 356.61
Fibonacci 38.2% 338.97
52-Week Low 281.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar